Ovid Therapeutics (OVID) Other Non-Current Assets (2016 - 2026)

Ovid Therapeutics (OVID) has reported Other Non-Current Assets for 11 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (changed 0.0% YoY), and the FY2025 full-year result was $1.9 million, changed 0.0% from the prior year.
• Other Non-Current Assets was little changed at $1.9 million in Q2 2026 per OVID's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.9 million in Q4 2023 and bottomed at $1.9 million in Q3 2022.
• Historically, Other Non-Current Assets has averaged $1.9 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 879.09% in 2022, then fell 0.03% in 2023.
• Over 5 years, Other Non-Current Assets stood at $1.9 million in 2022, then rose by 0.01% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.9 million, $1.9 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.